Search
Sabatolimab
go.drugbank.com/drugs/DB16322InvestigationalSabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic
Bleselumab
go.drugbank.com/drugs/DB15253InvestigationalBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney
Amprolium
go.drugbank.com/drugs/DB11374ExperimentalVet approvedAmprolium is a coccidiostat used in poultry.
Ulocuplumab
go.drugbank.com/drugs/DB12018InvestigationalUlocuplumab is under investigation in Solid Tumor.
Iguratimod
go.drugbank.com/drugs/DB12233InvestigationalIguratimod is under investigation in Rheumatoid Arthritis.
RGX-111
go.drugbank.com/drugs/DB17632InvestigationalDeveloped by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666] … RGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene.
Fenobam
go.drugbank.com/drugs/DB12931InvestigationalFenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance
GS-9191
go.drugbank.com/drugs/DB15084InvestigationalGS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
AVR-RD-01
go.drugbank.com/drugs/DB17651InvestigationalAVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. … AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.). … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.